首页> 外文期刊>Zeitschrift fur Gastroenterologie >Subclinical ascites defines an intermediate stage between compensated and decompensated cirrhosis
【24h】

Subclinical ascites defines an intermediate stage between compensated and decompensated cirrhosis

机译:亚临床腹水定义了代偿性和失代偿性肝硬化之间的中间阶段

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Clinical detection of ascites is a sign of decompensation and correlates with shorter survival in patients with cirrhosis. However, the prognostic relevance of sole detection of ascites by ultrasound (subclinical ascites) is not investigated so far. The aim of the study was to investigate the prognostic relevance of subclinical ascites detected by ultrasound in comparison to absent or clinically detectable ascites in patients with cirrhosis. Methods: Between 11/1995 and 11/2004a total of 729 patients with cirrhosis underwent sonographic and hemodynamic (including measurement of HVPG) evaluation. The mean follow up time was 47 months (range: 0.13 - 131). Kaplan-Meier survival curves and multivariate analysis were used to investigate differences. Results: 443 patients were included in the final investigation 153 patients without ascites, 38 with subclinical ascites and 252 patients with clinical ascites. Kaplan Meier survival curves were significantly different between the three groups (p < 0.001). Interestingly, patients with subclinical ascites had similar values compared to patients with clinical ascites regarding parameters of portal hypertension (HVPG) and liver dysfunction (INR), while parameters of systemic and renal dysfunction (heart beat, creatinin, serum sodium) were similar to patients without ascites. MELD, Child-Pugh score and ascites were independent predictors of mortality in the entire group, while Child-Pugh score and HVPG were independent factors in the subclinical ascites group. Conclusion: Detection of subclinical ascites by ultrasound allows the identification of a group of cirrhotic patients with intermediary survival compared to patients without or with clinical ascites. This group of patients is characterized by severe portal hypertension but absence of systemic and renal dysfunction.
机译:背景:腹水的临床检测是代偿失调的征兆,与肝硬化患者的生存期较短有关。然而,迄今为止,尚未研究通过超声单独检测腹水(亚临床腹水)的预后相关性。该研究的目的是调查与没有或临床上可检测到的肝硬化患者相比,超声检测亚临床腹水的预后相关性。方法:在11/1995年至11/2004年之间,对729例肝硬化患者进行了超声检查和血流动力学(包括HVPG测量)评估。平均随访时间为47个月(范围:0.13-131)。使用Kaplan-Meier生存曲线和多元分析来研究差异。结果:443例患者被纳入最终调查,其中153例无腹水,38例发生亚临床腹水,252例发生临床腹水。三组之间的Kaplan Meier生存曲线显着不同(p <0.001)。有趣的是,亚临床腹水患者在门脉高压(HVPG)和肝功能障碍(INR)参数方面与临床腹水患者具有相似的值,而全身和肾功能障碍(心跳,肌酐,血清钠)的参数与患者相似没有腹水。在整个组中,MELD,Child-Pugh评分和腹水是死亡率的独立预测因子,而在亚临床腹水组中,Child-Pugh评分和HVPG是独立因素。结论:与没有或没有临床腹水的患者相比,通过超声检测亚临床腹水可鉴定一组具有中等生存率的肝硬化患者。这组患者的特征是严重的门静脉高压症,但没有全身性和肾脏功能障碍。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号